Eagle Pharmaceuticals to Host First Quarter 2022 Financial Results on May 9, 2022
Eagle Pharmaceuticals (EGRX) is set to announce its first quarter financial results for 2022 on May 9, 2022, before the market opens. The conference call, hosted by CEO Scott Tarriff and CFO Brian Cahill, will take place at 8:30 a.m. ET. Investors can access the call via a toll-free number or through a webcast available on the company's investor relations page. The call will also be archived for 30 days. Eagle Pharmaceuticals focuses on developing innovative medicines, boasting a diverse pipeline of products aimed at enhancing patient care.
- None.
- None.
WOODCLIFF LAKE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 first quarter financial results on Monday, May 9, 2022, before the market opens.
Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:
| Date | Monday, May 9, 2022 |
| Time | 8:30 a.m. ET |
| Toll free (U.S.) | 800-891-3840 |
| International | 203-518-9544 |
| Webcast (live and replay) | www.eagleus.com, under the “Investor Relations” section |
A replay of the conference call will be available for two weeks after the call's completion by dialing 888-562-2826 (U.S.) or 402-220-7355 (International) and entering conference call ID EGRXQ122. The webcast will be archived for 30 days at the aforementioned URL.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include vasopressin, PEMFEXY™, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.
Contact:
Investor Relations for Eagle Pharmaceuticals, Inc:
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
When will Eagle Pharmaceuticals release its Q1 2022 financial results?
What time is the Eagle Pharmaceuticals conference call scheduled?
How can I access the Eagle Pharmaceuticals conference call?
Will there be a replay of the Eagle Pharmaceuticals conference call?
